science

Sotatercept

Sotatercept is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Sotatercept rather than just read about it. In short: Sotatercept, sold under the brand name Winrevair, is a medication used to treat pulmonary arterial hypertension. It inhibits activin signaling using the extracellular domain of the activin type 2 receptor fused with an immunoglobulin Fc domain (ACTRIIA-Fc) as a recombinant fusion protein.

Key takeaways

Sotatercept belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Sotatercept to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Sotatercept from memory before moving on to harder problems.

Reference excerpt

Sotatercept, sold under the brand name Winrevair, is a medication used to treat pulmonary arterial hypertension. It inhibits activin signaling using the extracellular domain of the activin type 2 receptor fused with an immunoglobulin Fc domain (ACTRIIA-Fc) as a recombinant fusion protein. It is administered via subcutaneous injection. The most common side effects include headache, epistaxis (nosebleed), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (redness of the skin). Sotatercept was approved for medical use in the United States in March 2024, and in the European Union in August 2024. The US Food and Drug Administration considers it to be a first-in-class medication.

Medical uses In the United States, sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (WHO group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and reduce the risk of clinical worsening events, including hospitalization for pulmonary arterial hypertension, lung transplantation and death. In the European Union, in combination with other pulmonary arterial hypertension therapies, sotatercept is indicated for the treatment of pulmonary arterial hypertension in adults with WHO Functional Class II to IV, to improve exercise capacity.

Side effects Common side effects include headache, epistaxis (nosebleeds), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (skin redness). Sotatercept increases hemoglobin levels, raising blood clot risk, and decreases platelet counts, potentially causing bleeding issues. Animal studies suggest it may impair fertility and cause fetal harm during pregnancy.

History The US Food and Drug Administration (FDA) approved sotatercept in March 2024, based on a trial of 323 participants with pulmonary arterial hypertension (WHO group 1, functional class II to IV) across 126 sites in 21 countries, including Argentina, Australia, and the United States. The study compared 163 participants on sotatercept to 160 on placebo, with 88 US participants (43 sotatercept, 45 placebo). The FDA granted the application for sotatercept breakthrough therapy designation. In August 2024, sotatercept was authorized for medical use in the European Union.

Society and culture

Economics In 2024, Winrevair's US list price was $14,000 per vial, with an annual cost of approximately $240,000 (actual costs vary by dose, body weight, insurance, discounts, assistance programs, and country). Based on the CDA-AMC clinical review of the STELLAR trial, sotatercept yields an incremental cost-effectiveness ratio of $436,796 per QALY gained, with cost-effectiveness highly dependent on uncertain long-term survival benefits and requiring an approximately 95% price reduction to meet a $50,000 per QALY threshold.

Names Sotatercept is the international nonproprietary name. Sotatercept is sold under the brand name Winrevair.

Research Initially developed to increase bone density, sotatercept was found to increase hemoglobin and red blood cell counts, leading to studies for anemia in beta thalassemia and multiple myeloma. Anemia research later shifted to luspatercept (Reblozyl), a modified activin receptor type 2B (ACTRIIB-Fc) ligand trap with better anemia treatment properties. Hypothesizing that sotatercept could block activin-driven pulmonary vascular disease, researchers found it inhibited vascular obliteration in experimental pulmonary hypertension models, leading to its evaluation in the PULSAR and STELLAR trials for pulmonary arterial hypertension.

References

Note

Further reading "Role of Sotatercept in Management of Pulmonary Arterial Hypertension: The STELLAR Trial". American College of Cardiology. Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; et al. (April 2021). "Sotatercept for the Treatment of Pulmonary Arterial Hypertension". New England Journal of Medicine. 384 (13): 1204–1215. doi:10.1056/NEJMoa2024277. PMID 33789009. Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; et al. (January 2022). "Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension". European Respiratory Journal. 61 (1). doi:10.1183/13993003.01347-2022. ISSN 0903-1936. PMC 9816418. PMID 36041750. Joshi, Sachindra R.; Liu, Jun; Bloom, Troy; Karaca Atabay, Elif; Kuo, Tzu-Hsing; Lee, Michael; et al. (May 2022). "Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension". Scientific Reports. 12 (1): 7803. Bibcode:2022NatSR..12.7803J. doi:10.1038/s41598-022-11435-x. ISSN 2045-2322. PMC 9098455. PMID 35551212. Komrokji, Rami; Garcia-Manero, Guillermo; Ades, Lionel; Prebet, Thomas; Steensma, David P; Jurcic, Joseph G; et al. (February 2018). "Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial". The Lancet Haematology. 5 (2): e63–e72. doi:10.1016/S2352-3026(18)30002-4. PMID 29331635. Yung, Lai-Ming; Yang, Peiran; Joshi, Sachindra; Augur, Zachary M.; Kim, Stephanie S.J.; Bocobo, Geoffrey A.l; et al. (May 2020). "ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension". Science Translational Medicine. 12 (543) eaaz5660. doi:10.1126/scitranslmed.aaz5660. PMC 8259900. PMID 32404506.

External links Clinical trial number NCT04576988 for "A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Sotatercept

Start with the simplest possible case. Write down what Sotatercept claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sotatercept before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sotatercept ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sotatercept

In research: Sotatercept appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Sotatercept in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Sotatercept is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antihypertensive agents, Drugs developed by Merck & Co., Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Sotatercept outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Sotatercept” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Sotatercept in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Sotatercept means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Sotatercept out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sotatercept in simple terms?

Why does Sotatercept matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sotatercept?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sotatercept.